Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication

NCT01696071

Last updated date
Study Location
205.441.43004 Boehringer Ingelheim Investigational Site
Grieskirchen, , , Austria
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Asthma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. All patients must sign and date an Informed Consent Form consistent with ICH-GCP guidelines and local legislation prior to participation in the trial.

2. Male or female patients aged at least 18 years at Visit 0 but not more than 75 years at Visit 0.

3. All patients must have at least a 3 months history of asthma at the time of enrolment (signing ICF) into the trial. The initial diagnosis of asthma must have been made before the patient's age of 40.

4. All patients must have a pre-bronchodilator FEV1 = 60% predicted and = 90% of predicted normal at Visit 1.Variation of absolute pre-bronchodilator FEV1 values at Visit 1 and Visit 2 must be within ± 30%.

5. Patient's diagnosis of asthma has to be confirmed at Visit 1 with bronchodilator reversibility (ie 10 minutes prior to and 15-30 minutes after inhalation of 400 µg salbutamol) defined as an FEV1 increase of = 12% and = 200 mL.

6. All patients must have a diagnosis of moderate persistent asthma and must be symptomatic despite their current maintenance treatment with medium doses of ICS.

7. All patients must be symptomatic at Visit 1and Visit 2 as defined by an ACQ mean score of = 1.5.

8. All patients must have maintenance treatment with stable medium daily dose of ICS for at least 4 weeks prior to Visit 1.

9. Patients must be never-smokers or ex-smokers who stopped smoking at least one year prior to enrolment (Visit 0) and who have a smoking history of less than 10 pack-years at Visit 0.

10. Patients must be able to use the Respimat inhaler correctly.

11. Patients must be able to perform all trial related procedures including technically acceptable pulmonary function tests and use of the AM3 (e-diary) compliance of at least 80% is required.

12. Patients taking a chronic pulmonary medication allowed by the study protocol must be willing to continue this therapy for the entire duration of the study (exception: times of acute disease deterioration).

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Patients with a significant disease other than asthma. A significant disease is
defined as a disease which, in the opinion of the investigator, may (i) put the
patient at risk because of participation in the trial, or (ii) influence the results
of the trial, or (iii) cause concern regarding the patient's ability to participate in
the trial.


2. Patients with a clinically relevant abnormal screening hematology or blood chemistry
at Visit 1 if the abnormality defines a significant disease as defined in exclusion
criterion no. 1.


3. Patients requiring more than 12 puffs of rescue medication (salbutamol MDI) per 24
hours for more than 2 consecutive days between Visit 1 and Visit 2 (screening period).


4. Patients with a recent history (ie six months or less) of Acute Coronary Syndrome
(STEMI, non-STEMI, Unstable Angina Pectoris) prior to Visit 1 (screening).


5. Patients who have been hospitalised for cardiac failure during the past year prior to
Visit 1 (screening).


6. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac
arrhythmia requiring intervention or a change in drug therapy within the past year
prior to Visit 1 (screening).


7. Patients with lung diseases other than asthma (eg COPD).


8. Patients with known active tuberculosis.


9. Patients with malignancy for which the patient has undergone resection, radiation
therapy or chemotherapy within the last five years prior to Visit 1 (screening).
Patients with treated basal cell carcinoma are allowed.


10. Patients who have undergone thoracotomy with pulmonary resection. Patients with a
history of thoracotomy for other reasons should be evaluated as per exclusion
criterion no. 1.


11. Patients with significant alcohol or drug abuse on Investigator's assessment within
the past two years prior to Visit 1 (screening).


12. Patients who are currently in a pulmonary rehabilitation program or have completed a
pulmonary rehabilitation program in the 6 weeks prior to Visit 1 (screening).


13. Patients with known hypersensitivity to anticholinergic drugs, BAC, EDTA or any other
components of the study medication delivery systems.


14. Pregnant or nursing women, including female patients with positive ß-HCG test at Visit
1.


15. Female patients of child-bearing potential not using highly effective method of birth
control. As defined in ICH (M3) [R09-1400], note 3, highly effective methods of birth
control are defined as those, alone or in combination, that result in a low failure
rate (ie less than 1% per year) when used consistently and correctly, such as
implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs),
sexual abstinence or vasectomised partner. Barrier contraceptives (eg male condom or
diaphragm) are acceptable if used in combination with spermicides (eg foam, gel).


Female patients will be considered to be of childbearing potential unless surgically
sterilised by hysterectomy or bilateral tubal ligation/salpingectomy, or
post-menopausal for at least two years.


16. Patients who have been treated with restricted medication prior to Visit 1 and/or
during the screening period.


17. Patients with any asthma exacerbation or any respiratory tract infection in the four
weeks prior to Visit 1 or during the screening period.


Visit 1 and/or Visit 2 should be postponed in case of an asthma exacerbation or
respiratory tract infection. Refer to Section 6.1 for information on re-scheduling of
visits.


18. Patients who are currently participating in another trial or who have been
participating in another trial within one month prior to Visit 0, and patients who
have previously been randomised in this trial.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

AsthmaEfficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma
NCT01122680
  1. Denver, Colorado
  2. Columbia, Missouri
  3. Warrensburg, Missouri
  4. Boys Town, Nebraska
  5. Canton, Ohio
  6. Koblenz,
  7. Rosenheim,
  8. Wesel,
  9. Balvi,
  10. Daugavpils,
  11. Rezekne,
  12. Riga,
  13. Riga,
  14. Vilnius,
  15. Vilnius,
  16. Vilnius,
  17. Kamnik,
  18. Ljubljana,
  19. Maribor,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
AsthmaRandomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.
NCT01233284
  1. Hallein,
  2. Linz,
  3. Neumarkt am Wallersee,
  4. Schlüsslberg,
  5. Thalheim bei Wels,
  6. Berlin,
  7. Berlin,
  8. Frankfurt,
  9. Hamburg,
  10. Hannover,
  11. Mainz,
  12. Schwerin,
  13. Wiesbaden,
  14. Wiesloch,
  15. Ivano-Frankivsk,
  16. Kharkiv,
  17. Kharkiv,
  18. Kiev,
  19. Kiev,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AsthmaEvaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
NCT00776984
  1. Fountain Valley, California
  2. Fresno, California
  3. Stockton, California
  4. Waterbury, Connecticut
  5. Pensacola, Florida
  6. Chicago, Illinois
  7. Normal, Illinois
  8. Louisville, Kentucky
  9. New Orleans, Louisiana
  10. Omaha, Nebraska
  11. Ocean, New Jersey
  12. Albany, New York
  13. Great Neck, New York
  14. Rockville Centre, New York
  15. High Point, North Carolina
  16. Canton, Ohio
  17. Upland, Pennsylvania
  18. Richmond, Virginia
  19. Concord, New South Wales
  20. Mississauga, Ontario
  21. Ottawa, Ontario
  22. Montreal, Quebec
  23. Aalborg,
  24. Aarhus C,
  25. Berlin,
  26. Hamburg,
  27. Lübeck,
  28. Rüdersdorf,
  29. Weinheim,
  30. Bussolengo (vr),
  31. Milano,
  32. Pavia,
  33. Pietra Ligure (sv),
  34. Himeji, Hyogo,
  35. Hiroshima, Hiroshima,
  36. Itabashi-ku, Tokyo,
  37. Kagoshima, Kagoshima,
  38. Kishiwada, Osaka,
  39. Kitakyusyu, Fukuoka,
  40. Koga, Fukuoka,
  41. Kurashiki, Okayama,
  42. Kurume, Fukuoka,
  43. Morioka, Iwate,
  44. Osaka-sayama, Osaka,
  45. Sendai, Miyagi,
  46. Seto, Aichi,
  47. Urasoe, Okinawa,
  48. Urasoe, Okinawa,
  49. Wakayama, Wakayama,
  50. Groningen,
  51. Leeuwarden,
  52. Schiedam,
  53. Auckland NZ,
  54. Christchurch,
  55. Newtown Wellington NZ,
  56. Tauranga,
  57. St. Petersburg,
  58. St. Petersburg,
  59. St. Petersburg,
  60. Belgrade,
  61. Nis,
  62. Sremska Kamenica,
  63. Bellville,
  64. Cape Town,
  65. Cape Town,
  66. Cape Town,
  67. Ankara,
  68. Ankara,
  69. Izmit,
  70. Kharkov,
  71. Kiev,
  72. Vinnytsya,
  73. Chertsey,
  74. Exeter,
  75. Windsor,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AsthmaA Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma
NCT01152450
  1. Linz,
  2. Schlüsslberg,
  3. Thalheim bei Wels,
  4. Wels,
  5. Brno,
  6. Kyjov,
  7. Kohtla-Järve,
  8. Tallinn,
  9. Großhansdorf,
  10. Hannover,
  11. Mannheim,
  12. Schwerin,
  13. Daugavpils,
  14. Riga,
  15. Riga,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication
Official Title  ICMJE A Randomised, Double- Blind, 2 Way Cross-over Study to Determine 24-hour FEV1-time Profile of Inhaled Tiotropium, Delivered Via the Respimat Inhaler, After 4 Weeks of Once Daily [5 mcg in the Evening (2 Actuations of 2.5 mcg)] or Twice Daily [2.5 mcg in the Morning and Evening (2 Actuations of 1.25 mcg)] Administration in Patients With Moderate Persistent Asthma.
Brief Summary Determine the 24-hour FEV1-profile of tiotropium solution for inhalation after 4 weeks treatment periods of 5 mcg tiotropium administered once daily in the evening and 2.5 mcg tiotropium administered twice daily (morning and evening). In addition compare the 24 hours pharmacokinetic profile of 5 mcg tiotropium administered once daily and 2.5mcg tiotropium administered twice daily in pharmacokinetic sub-investigation.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Asthma
Intervention  ICMJE
  • Drug: Tiotropium 5 mcg qd
    2 puffs (2.5 mcg each) in the evening 5 mcg in total and 2 puffs of matching placebo in the morning
  • Drug: Tiotropium 2.5 mcg bid
    2 puffs (1.25 mcg each) twice daily, in the evening and in the morning, 5 mcg in total
Study Arms  ICMJE
  • Experimental: Treatment A
    2 puffs of daily dose (5 mcg) in the evening and 2 puffs of matching placebo in the morning via Respimat inhaler
    Intervention: Drug: Tiotropium 5 mcg qd
  • Experimental: Treatment B
    2 puffs of half daily dose (2.5 mcg) twice daily, in the evening and in the morning via Respimat inhaler
    Intervention: Drug: Tiotropium 2.5 mcg bid
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 3, 2013)
98
Original Estimated Enrollment  ICMJE
 (submitted: September 26, 2012)
92
Actual Study Completion Date  ICMJE June 2013
Actual Primary Completion Date June 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria:

  1. All patients must sign and date an Informed Consent Form consistent with ICH-GCP guidelines and local legislation prior to participation in the trial.
  2. Male or female patients aged at least 18 years at Visit 0 but not more than 75 years at Visit 0.
  3. All patients must have at least a 3 months history of asthma at the time of enrolment (signing ICF) into the trial. The initial diagnosis of asthma must have been made before the patient's age of 40.
  4. All patients must have a pre-bronchodilator FEV1 = 60% predicted and = 90% of predicted normal at Visit 1.Variation of absolute pre-bronchodilator FEV1 values at Visit 1 and Visit 2 must be within ± 30%.
  5. Patient's diagnosis of asthma has to be confirmed at Visit 1 with bronchodilator reversibility (ie 10 minutes prior to and 15-30 minutes after inhalation of 400 µg salbutamol) defined as an FEV1 increase of = 12% and = 200 mL.
  6. All patients must have a diagnosis of moderate persistent asthma and must be symptomatic despite their current maintenance treatment with medium doses of ICS.
  7. All patients must be symptomatic at Visit 1and Visit 2 as defined by an ACQ mean score of = 1.5.
  8. All patients must have maintenance treatment with stable medium daily dose of ICS for at least 4 weeks prior to Visit 1.
  9. Patients must be never-smokers or ex-smokers who stopped smoking at least one year prior to enrolment (Visit 0) and who have a smoking history of less than 10 pack-years at Visit 0.
  10. Patients must be able to use the Respimat inhaler correctly.
  11. Patients must be able to perform all trial related procedures including technically acceptable pulmonary function tests and use of the AM3 (e-diary) compliance of at least 80% is required.
  12. Patients taking a chronic pulmonary medication allowed by the study protocol must be willing to continue this therapy for the entire duration of the study (exception: times of acute disease deterioration).

Exclusion criteria:

  1. Patients with a significant disease other than asthma. A significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the trial, or (ii) influence the results of the trial, or (iii) cause concern regarding the patient's ability to participate in the trial.
  2. Patients with a clinically relevant abnormal screening hematology or blood chemistry at Visit 1 if the abnormality defines a significant disease as defined in exclusion criterion no. 1.
  3. Patients requiring more than 12 puffs of rescue medication (salbutamol MDI) per 24 hours for more than 2 consecutive days between Visit 1 and Visit 2 (screening period).
  4. Patients with a recent history (ie six months or less) of Acute Coronary Syndrome (STEMI, non-STEMI, Unstable Angina Pectoris) prior to Visit 1 (screening).
  5. Patients who have been hospitalised for cardiac failure during the past year prior to Visit 1 (screening).
  6. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year prior to Visit 1 (screening).
  7. Patients with lung diseases other than asthma (eg COPD).
  8. Patients with known active tuberculosis.
  9. Patients with malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years prior to Visit 1 (screening). Patients with treated basal cell carcinoma are allowed.
  10. Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion no. 1.
  11. Patients with significant alcohol or drug abuse on Investigator's assessment within the past two years prior to Visit 1 (screening).
  12. Patients who are currently in a pulmonary rehabilitation program or have completed a pulmonary rehabilitation program in the 6 weeks prior to Visit 1 (screening).
  13. Patients with known hypersensitivity to anticholinergic drugs, BAC, EDTA or any other components of the study medication delivery systems.
  14. Pregnant or nursing women, including female patients with positive ß-HCG test at Visit 1.
  15. Female patients of child-bearing potential not using highly effective method of birth control. As defined in ICH (M3) [R09-1400], note 3, highly effective methods of birth control are defined as those, alone or in combination, that result in a low failure rate (ie less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomised partner. Barrier contraceptives (eg male condom or diaphragm) are acceptable if used in combination with spermicides (eg foam, gel).

    Female patients will be considered to be of childbearing potential unless surgically sterilised by hysterectomy or bilateral tubal ligation/salpingectomy, or post-menopausal for at least two years.

  16. Patients who have been treated with restricted medication prior to Visit 1 and/or during the screening period.
  17. Patients with any asthma exacerbation or any respiratory tract infection in the four weeks prior to Visit 1 or during the screening period.

    Visit 1 and/or Visit 2 should be postponed in case of an asthma exacerbation or respiratory tract infection. Refer to Section 6.1 for information on re-scheduling of visits.

  18. Patients who are currently participating in another trial or who have been participating in another trial within one month prior to Visit 0, and patients who have previously been randomised in this trial.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Austria,   Germany,   Hungary,   Slovenia
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01696071
Other Study ID Numbers  ICMJE 205.441
2012-001873-10 ( EudraCT Number: EudraCT )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Boehringer Ingelheim
Study Sponsor  ICMJE Boehringer Ingelheim
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Chair:Boehringer IngelheimBoehringer Ingelheim
PRS Account Boehringer Ingelheim
Verification Date July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP